Koyfin Home > Directory > Health Care > Revance Therapeutics > Cash from Financing Activities

Revance Therapeutics Cash from Financing Activities Chart (RVNC)

Revance Therapeutics annual/quarterly Cash from Financing Activities from 2012 to 2020.
  • Revance Therapeutics Cash from Financing Activities for the quarter ending June 06, 2020 was $1m a 116.20% increase of 1m year over year
  • Revance Therapeutics Cash from Financing Activities for the last 12 months ending June 06, 2020 was $380m a 71.81% increase of 273m year over year
  • Revance Therapeutics Annual Cash from Financing Activities for 2019 was $222m a 99.20% increase of 220m from 2018
  • Revance Therapeutics Annual Cash from Financing Activities for 2018 was $2m a -10,895.74% decrease of -194m from 2017
  • Revance Therapeutics Annual Cash from Financing Activities for 2017 was $196m a 101.35% increase of 199m from 2016
Other Cash Flow Metrics:
  • Revance Therapeutics Cash Flow from Operations for the quarter ending September 09, 2018 was $-25m a -11.78% increase of 3m year over year
  • Revance Therapeutics Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $-14m a -14.44% increase of 2m year over year
  • Revance Therapeutics Total Revenue for the quarter ending September 09, 2018 was $2m a 98.43% increase of 2m year over year
View Chart On Koyfin

Quarterly RVNC Cash from Financing Activities Data

06/2020$1m
03/2020$264m
12/2019$115m
09/2019$0m
06/2019$0m
03/2019$107m
12/2018$0m
09/2018$1m
06/2018$3m
03/2018$-2m

Annual RVNC Cash from Financing Activities Data

2019$222m
2018$2m
2017$196m
2016$-3m
2015$143m
2014$229m
2013$54m
2012$14m
2011$54m